What is Zacks Research’s Estimate for Amgen FY2025 Earnings?

Amgen Inc. (NASDAQ:AMGN) – Equities research analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Amgen in a report issued on Tuesday, November 25th. Zacks Research analyst Team now forecasts that the medical research company will earn $21.20 per share for the year, up from their previous forecast of $20.80. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. Zacks Research also issued estimates for Amgen’s Q4 2025 earnings at $4.64 EPS and Q2 2026 earnings at $5.34 EPS.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same period in the previous year, the company posted $5.58 EPS. The company’s revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS.

Several other equities research analysts have also issued reports on AMGN. Morgan Stanley dropped their price objective on shares of Amgen from $333.00 to $329.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 5th. Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Citigroup raised their price objective on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research report on Wednesday, September 24th. HSBC boosted their price objective on Amgen from $343.00 to $381.00 and gave the stock a “buy” rating in a research note on Wednesday, November 19th. Finally, Raymond James Financial started coverage on Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating for the company. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $333.74.

Amgen Trading Up 1.0%

NASDAQ AMGN opened at $344.57 on Thursday. The firm has a market capitalization of $185.54 billion, a price-to-earnings ratio of 28.17, a PEG ratio of 2.61 and a beta of 0.45. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. Amgen has a one year low of $253.30 and a one year high of $345.84. The company’s 50 day moving average price is $304.95 and its 200 day moving average price is $293.90.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be paid a $2.38 dividend. The ex-dividend date is Friday, November 21st. This represents a $9.52 annualized dividend and a dividend yield of 2.8%. Amgen’s payout ratio is 73.57%.

Insider Activity at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares in the company, valued at $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 10,908 shares of company stock valued at $3,674,966. Insiders own 0.76% of the company’s stock.

Institutional Trading of Amgen

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wealth Preservation Advisors LLC acquired a new position in Amgen during the 1st quarter worth $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the second quarter worth about $27,000. CBIZ Investment Advisory Services LLC grew its stake in Amgen by 1,214.3% in the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock worth $29,000 after purchasing an additional 85 shares in the last quarter. Evelyn Partners Investment Management LLP bought a new stake in Amgen in the second quarter valued at about $32,000. Finally, Howard Hughes Medical Institute bought a new stake in Amgen in the second quarter valued at about $32,000. Institutional investors own 76.50% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.